Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript [Seeking Alpha]
Imunon, Inc. (IMNN)
Company Research
Source: Seeking Alpha
Company Participants Stacy Lindborg - President, CEO & Director Douglas V. Faller - Chief Medical Officer Conference Call Participants Premal Thaker Amir Jazaeri Giorgio Paulon James Molloy - Alliance Global Partners, Research Division Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division Presentation Stacy Lindborg President, CEO & Director All right. Good morning, everyone. I'm Stacy Lindborg. I'm the CEO of Imunon, and it is my true honor to get to welcome you to the 2025 Imunon R&D Day. As I look across the people in the room and certainly have reviewed the -- those that registered online for the live webcast, we have esteemed guests here and investors and partners, which we're delighted by. So we'll be showcasing IMNN-001's progress with our novel immunotherapy, IMNN-001. But what really matters is our goal. And we are in pursuit of the first immunotherapy that will be approved for frontline advanced ovarian cancer. The enthusiasm that I feel and
Show less
Read more
Impact Snapshot
Event Time:
IMNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNN alerts
High impacting Imunon, Inc. news events
Weekly update
A roundup of the hottest topics
IMNN
News
- Imunon (NASDAQ:IMNN) had its "buy" rating reaffirmed by analysts at Brookline Capital Management.MarketBeat
- IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules [Yahoo! Finance]Yahoo! Finance
- IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ RulesGlobeNewswire
- IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026 [Yahoo! Finance]Yahoo! Finance
- IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026GlobeNewswire
IMNN
Sec Filings
- 1/7/26 - Form 8-K
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- IMNN's page on the SEC website